How We Work
From Choices to Execution
Most drug development programs fail not because of bad science, but because of unclear strategy. We bring a rigorous framework to every engagement, connecting the choices you make today to the outcomes you need tomorrow.
Book a Discovery Call
Our Philosophy
Strategy Is Choices
We help you make them. Every drug development program faces hundreds of decisions. Which indication to pursue. Which endpoints to measure. Which regulatory pathway to follow. Most teams treat these as operational questions. They are strategic ones.
“Strategy is not a lengthy action plan. It is the evolution of a central idea through continually changing circumstances.”
Jack Welch, adapted for drug development
Our role is to bring clarity to complexity. We connect strategy to execution so that every experiment, every study, every dollar spent moves your program forward with purpose.
The Framework
The Strategic Choice Cascade
Adapted from Roger Martin and A.G. Lafley's “Playing to Win” framework for drug development. Five integrated choices that build on each other to create a coherent strategy.
Winning Aspiration
What does winning look like for your program?
Define the ultimate outcome. Not vague ambitions, but a concrete picture of success for your molecule, your patients, and your organization.
Where to Play
Which patient population, disease, geography, preclinical evidence?
Choose your playing field deliberately. The right indication, the right population, the right regulatory pathway. These choices shape everything downstream.
How to Win
What makes your approach unique?
Differentiation or cost advantage? Novel mechanism or better delivery? Your competitive advantage must be explicit, defensible, and grounded in evidence.
Capabilities
What resources, technology, expertise do you need?
Identify the capabilities required to execute your strategy. Then assess honestly which ones you have, which ones you need, and which ones you must build or acquire.
Management Systems
What processes support execution?
Strategy without execution is a wish list. Define the decision frameworks, review cycles, and governance structures that keep your program on track.
A Critical Distinction
What Strategy Is NOT
Most teams confuse strategy with other important things. This confusion leads to programs that feel busy but lack direction.
Strategy is NOT
- Goals and aspirations
- Plans and experimental workflows
- Mission and vision statements
- A list of activities and initiatives
- A budget or financial forecast
Strategy IS
- Explicit choices about what you will do
- Equally explicit choices about what you will not do
- A theory of how you will win
- A coherent set of mutually reinforcing decisions
- A living framework that adapts to new evidence
When you confuse strategy with planning, you end up with a detailed schedule and no clear direction. We make sure that does not happen.
The Process
How Every Engagement Works
Four stages. Clear milestones. No ambiguity about what happens next.
Discovery Call
30 minutes, complimentary
We start by listening. You share your science, your goals, your constraints. We ask the questions that reveal where strategy can create the most impact.
Landscape & Gap Analysis
1 to 2 weeks
We map the competitive landscape, review regulatory precedents, and identify the evidence gaps standing between your molecule and a clear development path.
Strategy Design & Delivery
2 to 4 weeks
We build your development plan: milestones, go/no-go criteria, regulatory pathway, and budget framework. Every recommendation traces back to evidence and strategic logic.
Ongoing Advisory
Optional retainer
Data changes. Markets shift. Regulations evolve. We stay alongside you to adapt your strategy as new information emerges. Because strategy is never finished.
What You Receive
Deliverables That Drive Decisions
Every engagement produces tangible artifacts. Documents you can share with investors, present to regulators, and use to align your team.
Strategy on a Page
One page that captures the five strategic choices in a single view. Replaces the 200-page deck.
Contents
- Winning aspiration
- Where to play (indication, population, geography)
- How to win (mechanism, evidence, differentiation)
- Required capabilities and gaps
- Management cadence and decision rights
Format · One-page PDF with editable source. Reviewed quarterly.
Target Product Profile
TPP or Platform Target Profile aligned to FDA and EMA structure. Defines what the product must achieve to win.
Contents
- Indication, population, line of therapy
- Efficacy endpoints and clinical thresholds
- Safety profile and tolerability bounds
- Route, dose, formulation, regimen
- Differentiation versus standard of care
Format · Annotated TPP document. Updated at each go/no-go gate.
Development Roadmap
Milestone-driven plan from preclinical evidence to first regulatory submission. Stages, dependencies, data readouts.
Contents
- Phase-by-phase milestones and durations
- Critical-path studies and dependencies
- Data readouts and decision points
- Submission anchors (IND, CTA, BLA, MAA)
- Risk register with mitigation owners
Format · Timeline view with narrative companion. Refreshed at each program review.
Go/No-Go Framework
Pre-agreed decision criteria at each critical junction. Removes ambiguity about when to advance, pivot, or stop.
Contents
- Criterion definitions per gate
- Quantitative pass/fail thresholds
- Decision owner and signatories
- Escalation path and timing
- Pre-defined pivot and stop options
Format · Decision matrix per gate. Signed off before each phase begins.
Regulatory Pathway
Agency strategy with precedent analysis. FDA, EMA, PMDA, MHRA — chosen with rationale, not by default.
Contents
- Agency selection and sequencing
- Designation strategy (Fast Track, PRIME, Breakthrough, ATMP)
- Precedent programs and lessons
- Pre-submission interaction plan
- Briefing book outline
Format · Regulatory strategy memo with precedent appendix.
Budget Framework
Resource allocation tied to strategic choices. Funding follows clarity, not the other way around.
Contents
- Multi-year allocation by phase and workstream
- Base, upside, and downside sensitivities
- Tradeoff scenarios (scope, speed, cost)
- Contingency reserve and triggers
- Funding milestones for investor conversations
Format · Multi-year model with one-page executive summary.
Ready to Make Strategic Choices?
The first step is a 30-minute discovery call. No cost, no commitment. Just clarity on whether we can help your program move forward.
Book a Free Discovery Call